Licensing is a required step in the pharma industry, and unfortunately, it can be incredibly complicated. The consequences for not carrying the correct license can range from fines to an immediate stop in sales to felony charges – and that’s just the beginning.
The Drug Supply Chain Security Act (DSCSA), passed in November 2013, has become a buzzword in the pharma industry in the past few years, and will continue to be until the completion of the implementation in 2023.
The results of these searches tend to center around licensing: in-licensing, out-licensing, drug licensing, and facility licensing. How does all of this relate to launching a drug?
In the pharmaceutical industry, a "Price Book" is often synonymous with Compendia data. Even though physical publications were discontinued more than 15 years ago, people in the industry still use the term "Price Book."
Electronic prescribing allows healthcare providers to manage prescriptions electronically, making prescriptions safe, convenient and fast (SureScripts).
But what if there’s an issue with your new product launch?
Two Labs Marketing, LLC is announcing our name change to Two Labs, LLC, a pharma services consulting company. To some it might sound like a small change, but to those who have been around Two Labs Marketing know that for over 14 years we have evolved into much more and we want our name to reflect that.
Within the autoimmune space, payers face difficult challenges in decision making. This category has non-exhaustive and non-exclusive populations, making management by indication burdensome.
This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents.
